[email protected]   +1 (304) 306-0723

Central Precocious Puberty | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030 (Copy)

$6,500.00$19,500.00

Growth of the diagnosed CPP population will contribute to increasing sales in the CPP therapy market over our forecast period. An estimated annual growth rate of 0.12% in the diagnosed CPP population across the major pharmaceutical markets will contribute to increasing CPP therapy sales. In 2019, there were approximately xx diagnosed cases of CPP in the major markets; we expect the number of cases will exceed xx in 2030 owing to changes in population demographics and increasing awareness related to this rare disease.
Strong Uptake of the 6-months Leuprolide acetate (Fensolvi) will be driven by the need for an alternative therapy for 3-months depot Leuprolide acetate and will contribute to the growth of the CPP market. We expect leuprolide acetate to be preferentially prescribed to patients. However, as physicians become more familiar with the agent, we expect Fensolvi to gain more patient share. The drug is forecasted to earn sales of $xx million in 2030 .
Clear

Description

Central precocious puberty / CPP ( also known as Gonadotropin-dependent precocious puberty (GDPP) or true precocious puberty) results from the premature activation of the hypothalamic-pituitary-gonadal axis. It mimics physiological pubertal development, although at an inappropriate chronological age (before 8 years in girls and 9 years in boys).

In GnRH-dependent precocious puberty, the hypothalamic-pituitary axis is activated, resulting in enlargement and maturation of the gonads, development of secondary sexual characteristics, and oogenesis or spermatogenesis.

Central precocious puberty (CPP) Epidemiology

CPP has an incidence of 1 in 5-10,000 children with a female to male ratio of about 20:1 although this ratio is debated. Eighty to ninety percent of girls with true PP (precocious puberty) have idiopathic CPP whereas over 50% of boys have an identifiable etiology for true PP. In 2020, the estimated CPP cases in US are the highest followed by European 5 countries (Germany, France, Italy, Spain & UK) and Japan.
Total treated cases of CPP will also rise from ~8000 cases in 2019 to xxx in 2030 in the G7 countries due to the rising awareness of the disease, expected launch and expanded use of the long-acting potential therapies, which will shift the market from short term treatments to the effective long-term treatments.

As per multiple studies, Idiopathic CPP are the most common form of CPP. The environmental pollutants, especially the pesticides have been known to behave as estrogen-like and androgens antagonist. These pollutants act as endocrine disruptors and have estrogenic, antiestrogenic, androgenic, and antiandrogenic effect on puberty and directly on the GnRH system.

Incidence Cases of CPP
Incidence Cases of CPP

Central precocious puberty (CPP) Market Forecast

The Central Precocious Puberty (CPP) therapy market is expected to experience moderate growth throughout our study period, increasing from $xxx million in 2019 to $xxx million in 2030, representing 5.43% annual growth. Primary drivers of this growth will be uptake of the novel 6 months treatment i.e., Triptorelin 6-month Formulation (Arbor’s Triptodur) and the Leuprolide Acetate (LA) 6-month Formulation (Tolmar’s Fensolvi), along with an expanding number of diagnosed and treated CPP cases, predominantly in the United States.
The Leuprolide Acetate (AbbVie’s Lupron) accounts for the larger segment of the drug-treated CPP population share. In 2019, sales of Leuprolide Acetate therapies accounted for approximately 65% of major-market CPP sales because of the physician’s preference over the surgical treatments. In addition, patients also undergo surgical treatment with Histrelin Subcutaneous Implant (Endo’s Supprelin LA) , which accounts for 31% of the total market share in 2019. The long-term use of Leuprolide Acetate, newer 6 months formulation therapies —and, to a lesser extent, generic and Synarel, Zoladex and other therapies—will drive sales of CPP market from $xxx million in 2019 to $xxx million in 2030.
Market Size of CPP-UK- Mellata meets
Market Size of CPP-UK- Mellata meets

Report Highlights

  • Central Precocious Puberty (CPP) Current Market Trends
  • Central Precocious Puberty (CPP) Current & Forecasted Cases across the G7 Countries
  • Central Precocious Puberty (CPP) Market Opportunities And Sales Potential for Agents
  • Central Precocious Puberty (CPP) Patient-based Market Forecast to 2030
  • Central Precocious Puberty (CPP) Untapped Business Opportunities
  • Central Precocious Puberty (CPP) Product Positioning Vis-a-vis Competitors’ Products
  • Central Precocious Puberty (CPP) KOLs Insight

Additional information

Price

2-3 User License, Enterprise License, Single User License, Site User License

Table of Contents

  • Central Precocious Puberty Disease Background
    • Central Precocious Puberty Definition
    • Symptoms
    • Risk Factor
    • Diagnosis
  • Epidemiology Estimated and Forecast to 2030
    • Epidemiology Research Method & Data Sources Used
      • Incident Cases of Central Precocious Puberty in the United States 2020-2030
      • Diagnosed & Treated Cases of Central Precocious Puberty in the United States 2020-2030
      • Incident Cases of Central Precocious Puberty in Germany 2020-2030
      • Diagnosed & Treated Cases of Central Precocious Puberty in Germany 2020-2030
      • Incident Cases of Central Precocious Puberty in France 2020-2030
      • Diagnosed & Treated Cases of Central Precocious Puberty in France 2020-2030
      • Incident Cases of Central Precocious Puberty in Italy 2020-2030
      • Diagnosed & Treated Cases of Central Precocious Puberty in Italy 2020-2030
      • Incident Cases of Central Precocious Puberty in Spain 2020-2030
      • Diagnosed & Treated Cases of Central Precocious Puberty in Spain 2020-2030
      • Incident of Central Precocious Puberty in the United Kingdom 2020-2030
      • Diagnosed & Treated Cases of Central Precocious Puberty in the United Kingdom 2020-2030
      • Incident Cases of Central Precocious Puberty in Japan 2020-2030
      • Diagnosed & Treated Cases of Central Precocious Puberty in Japan 2020-2030
  • Current Unmet Needs in Central Precocious Puberty
  • Current Treatment Paradigm
    • Treatment guidelines for Central Precocious Puberty
    • Current Therapies Chapters
      • Leuprolide Acetate (LA) –AbbVie
      • Histrelin Subcutaneous Implant –Endo Pharmaceuticals
      • Triptodur –Arbor Pharmaceuticals/Debiopharm International SA
      • Fensolvi –Tolmar Pharmaceuticals
  • Emerging Therapies Chapters
    • Leuprolide Acetate (LA)-6months Formulation –AbbVie
  • CPP Product Positioning
    • Key Competitors
    • Matrix Modeling
    • KOLs Insight (US, EU, JP)
      • Unmet Needs
      • Analysis of the progresses in terms of approvals;
      • Impact on the treatment algorithm and product positioning
      • Relevance of Therapy Uptake Share %
      • Physicians Preferences for the new pharmacological agents
  • Total Market Forecast
    • Key Summary Findings
      • G7 total Market for Central Precocious Puberty 2020-2030 (USD Million)
      • G7 total Market for Central Precocious Puberty by Therapies 2020-2030 (USD Million)
  • Market Forecast by Country
    • United States
      • United States Market for Central Precocious Puberty 2020-2030 (USD Million)
      • United States Market for Central Precocious Puberty by Therapies 2020-2030 (USD Million)
    • Germany
      • Germany Market for Central Precocious Puberty 2020-2030 (USD Million)
      • Germany Market for Central Precocious Puberty by Therapies 2020-2030 (USD Million)
    • France
      • France Market for Central Precocious Puberty 2020-2030 (USD Million)
      • France Market for Central Precocious Puberty by Therapies 2020-2030 (USD Million)
    • Italy
      • Italy Market for Central Precocious Puberty 2020-2030 (USD Million)
      • Italy Market for Central Precocious Puberty by Therapies 2020-2030 (USD Million)
    • Spain
      • Spain Market for Central Precocious Puberty 2020-2030 (USD Million)
      • Spain Market for Central Precocious Puberty by Therapies 2020-2030 (USD Million)
    • United Kingdom
      • United Kingdom Market for Central Precocious Puberty 2020-2030 (USD Million)
      • United Kingdom Market for Central Precocious Puberty by Therapies 2020-2030 (USD Million)
    • Japan
      • Japan Market for Central Precocious Puberty 2020-2030 (USD Million)
      • Japan Market for Central Precocious Puberty by Therapies 2020-2030 (USD Million)
  • Market Drivers & Barriers
  • Appendix
  • About Mellalta Meets
Name
Email
Phone
Enquiry

You may also like…

Get In Touch

Let's keep the conversation going